Live
Endpoints NewsGSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B10x Genomics Blog10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan10x Genomics Blog10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock TitanFierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEli LillyBig Pharma Stock Eli Lilly Concocts New Buy Zone - Investor's Business DailyEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsVertexKyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech Investing - News and Statistics - IndexBox
Endpoints News 6 déc. 2025

ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more

ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more

Original
Contenu indisponible. Consultez la source originale.